Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Neuritis, Radiofrequency Ablation
Interventions: Dexamethasone 4 mg/ml, Normal saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anal Cancer, Precancerous Condition
Interventions: cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination; Drug · Genetic · Procedure
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years to 120 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Major Cutaneous Abscess, Cellulitis, Erysipelas
Interventions: TR701 FA; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Anaheim, California • Buena Park, California • Chula Vista, California + 7 more

Conditions: Smoking Cessation, Tobacco Use Disorder
Interventions: Usual Care, Smoking Reduction; Drug · Other
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 13 Years to 19 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Cancer
Interventions: Bronchoalveolar Lavage (BAL) during Bronchoscopy; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone; Procedure · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ovulation Suppression
Interventions: levonorgestrel and ethinyl estradiol; Drug
Lead sponsor: Agile Therapeutics; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 11
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more

Conditions: Accuracy of Tissue Diagnosis, Bile Duct Stricture, Pancreatic Duct Stricture
Interventions: ERCP with cholangiopancreatoscopy; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Testosterone Transdermal System, Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Contraception
Interventions: Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Low Back Pain
Interventions: Lidoderm®; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 6
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 3 more

Conditions: Breast Cancer
Interventions: Biomarkers; Other
Lead sponsor: Sentara Norfolk General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Newport News, Virginia • Norfolk, Virginia

Conditions: Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
Interventions: AU-011, Suprachoroidal Microinjector, PDT Laser; Drug · Device
Lead sponsor: Aura Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions: Coronary artery stenting: Absorb BVS; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Scottsdale, Arizona • Petoskey, Michigan

Conditions: Smoking Cessation, Tobacco Use Cessation, Tobacco Smoking
Interventions: Nicorette, Tobacco Quit-line, Brief Behavioral Counseling, Intensive Behavioral Counseling; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Recurrence
Interventions: Argon Plasma Coagulation, Snare Tip Soft Coagulation; Device
Lead sponsor: Indiana University; Other
Eligibility: 25 Years and older
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Orlando, Florida • Indianapolis, Indiana + 5 more

Conditions: Gastroparesis
Interventions: Granisetron; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer, Breast Diseases
Interventions: Evaluation of BIT-Motion software; Diagnostic Test
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Calcinosis
Interventions: Fractionated Carbon Dioxide (FCO2) Laser, Sodium thiosulfate; Device · Drug
Lead sponsor: Alison Ehrlich; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Idiopathic CD4 T Cell Lymphocytopenia
Interventions: Gardasil 9; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PCOS, Polycystic Ovary Syndrome
Interventions: Micronized progesterone, Placebo, Flutamide, Estradiol patch; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Contraception, Contraception Behavior
Interventions: Intervention Group, Control Group; Diagnostic Test · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 15 Years to 21 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tattoos
Interventions: Describe patch; Device
Lead sponsor: ON Light Sciences; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking Cessation
Interventions: Telephone counseling, Nicotine patches, Incentive; Behavioral · Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 3,816 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2

Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

Early Detection of Breast Cancer in Women With Suspicious Mammograms

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions

Smoking Cessation Program in the Construction Sector

Post-resection Treatment of Large Colon Polyps

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

Advanced Diffusion Tensor MRI for Breast Cancer

Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

Contraception Initiation Feasibility in the Pediatric ED

Evaluation of the Safety and Efficacy of the DeScribe™ Patch

A Randomized Trial of Medi-Cal Beneficiaries Calling the California Smokers' Helpline